Zhenping Zhu, n/a

Helixon Therapeutics
New York, United States

Presentation(s):

• 0018: Development of a noval ‘1+1+1’ CD19- and BCMA-dual targeted T cell engager for autoimmune diseases

  Sunday, October 26, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure information not submitted.

• 1006: Ai-guided Generation and Preclinical Evaluation of an OX40L-IL31 Bispecific Antibody

  Monday, October 27, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure information not submitted.